CRA was retained by a pharmaceutical company to assist in settlement negotiations with a potential generic competitor. As part of this project, CRA prepared a flexible valuation model to estimate the expected profits from the perspective of the generic competitor under various assumptions. CRA also prepared a decision probability tree analysis to address issues related to litigation risk, acceptable date of generic entry and the impact of an authorized generic.
Update on the Texas Business Court: July 2025
The Texas Business Court was formed in September 2024 as a specialized court that aims to provide a more efficient and predictable environment for resolving...